People

Apollo Health Ventures current own career biography: Nils co-founded Apollo Health Ventures in 2017 and is one of the most successful German investors and a serial entrepreneur with six exits since 2009 He utilizes his deal-making skills, impeccable business sense, and his expertise in growing early-stage startups to support the Apollo portfolio Nils and the founding team have successfully raised two fund generations, hired the senior team, and led investments as well as follow-on investments in Apollo's portfolio companies Nils studied business in Hamburg and at UC Santa Barbara (UCSB) in California, and he completed the EO Entrepreneurial Masters Program at MIT Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.

Keith Brady, JD, is Vice President of Sales at AppliedVR, leading sales growth and revenue expansion.

Myles Guanzon is Vice President of Engineering at AppliedVR, a product development executive with more than 15 years of experience in digital health.

Todd Maddox, PhD, is Vice President of Research and Development at AppliedVR. He applies brain science, data and psychology to immersive therapeutics. AppliedVR's official NIH SBIR awards identify him as principal investigator William T. Maddox.

Beth Darnall, PhD, is Chief Science Advisor at AppliedVR. Her work centers on pain treatment methodologies that empower patients.

Stevie Cogan is Head of People at AppliedVR, responsible for company culture, talent and people development.

Oliver Koechli is Chief Operating Officer of AppliedVR, overseeing day-to-day operations and administrative efficiency.

Josh Sackman is co-founder and President of AppliedVR. His work at the intersection of healthcare and technology and his experience as a pediatric patient informed the company's focus on accessible pain management.

Matthew Stoudt is co-founder and CEO of AppliedVR, which he founded in 2015. His earlier entrepreneurial work was in digital media; he now leads the company's immersive therapeutics business.

Jürgen Blumberg is Head of Business Development at NaroIQ, according to his announcement republished by the company. He previously joined its expert board before expanding his contribution into a full-time business development role.

Leona Turner is listed by NaroIQ as Chief of Staff. NaroIQ develops digital infrastructure for ETFs and investment funds.

Tim Entenmann is listed by NaroIQ as Product. NaroIQ develops digital infrastructure for ETFs and investment funds.

Nils Krauthausen co-founded NaroIQ with Chris Puellen in 2022. The company builds digital infrastructure for launching and administering ETFs and investment funds. Its current homepage does not publish a present executive title for Krauthausen.

Seda Tunç Soylu is listed by NaroIQ as Head Of Fixed Income. NaroIQ develops digital infrastructure for ETFs and investment funds.

Christian Meyer-Vahrenhorst is listed by NaroIQ as Managing Director. NaroIQ develops digital infrastructure for ETFs and investment funds.

Hendrik Mechlinski is listed by NaroIQ as Managing Director. NaroIQ develops digital infrastructure for ETFs and investment funds.

Nico Hamann is listed by NaroIQ as Head Of Indexing. NaroIQ develops digital infrastructure for ETFs and investment funds.

Chris Puellen is listed by NaroIQ as CEO and Co-Founder. NaroIQ develops digital infrastructure for ETFs and investment funds.

Moritz Schierholz is listed by NaroIQ as Head Of Portfolio Management. NaroIQ develops digital infrastructure for ETFs and investment funds.

Kip Quackenbush is listed by Sway Capital as Advisor, Sway Studios. The published role is advisory; no personal cash investment is inferred.

Andy Bair is listed by Sway Capital as Advisor, Sway Ventures. The published role is advisory; no personal cash investment is inferred.

Yasmin Moaven is listed by Sway Capital as Advisor, Sway Ventures. The published role is advisory; no personal cash investment is inferred.

David Dill is listed by Sway Capital as Advisor, Sway Ventures. The published role is advisory; no personal cash investment is inferred.

Marwan Fawaz is listed by Sway Capital as Advisor, Sway Ventures. The published role is advisory; no personal cash investment is inferred.

Donna Wells is listed by Sway Capital as Advisor, Sway Ventures. The published role is advisory; no personal cash investment is inferred.

Karl Wagner is listed by Sway Capital as Advisor, Sway Ventures. The published role is advisory; no personal cash investment is inferred.

Sam Howard is listed by Sway Capital as Principal, Sway Capital. This affiliation is engaged pursuant to an agreement with an outsourced shared-services provider.

Najwa Nasif is listed by Sway Capital as Manager of People, Sway Capital. This affiliation is engaged pursuant to an agreement with an outsourced shared-services provider.

Jessica Gonzalez is listed by Sway Capital as Accountant, Sway Capital. This affiliation is engaged pursuant to an agreement with an outsourced shared-services provider.

Bret Awbrey is listed by Sway Capital as VP, Finance, Sway Capital. This affiliation is engaged pursuant to an agreement with an outsourced shared-services provider.

John McGuinness is listed by Sway Capital as Partner, GC & CCO, Sway Capital. This affiliation is engaged pursuant to an agreement with an outsourced shared-services provider.

Thalia Gietzen is listed by Sway Capital as CFO, Sway Capital. This affiliation is engaged pursuant to an agreement with an outsourced shared-services provider.

Megan Ellertson is listed by Sway Capital as Office Manager, Executive Administration, Sway Capital.

Louay Karana is listed by Sway Capital as Sr. Accounting Manager, Sway Capital.

Kathleen Hamil is listed by Sway Capital as Manager, Fund Administration, Sway Capital.

Nicholas Ferrall is listed by Sway Capital as Strategic Advisor, Sway Media. The published role is advisory; no personal cash investment is inferred.

Tobin Armbrust is listed by Sway Capital as Producer, Sway Media.

Nick Johnson is listed by Sway Capital as Associate, Sway Capital.

Brennan Reif is listed by Sway Capital as Principal, Sway Capital.

Terrence Battle is listed by Sway Capital as Sr. Principal, Sway Studios.

Vincent Monteparte is listed by Sway Capital as Venture Partner, Sway Ventures.

Domini Kelly is listed by Sway Capital as Partner, Fund Administration, Sway Capital.

Lani ONeill is listed by Sway Capital as Partner, Sway Capital.

Patrick ONeill is listed by Sway Capital as Partner, CMO, Sway Capital.

Albert Vazquez-Agusti is listed by Sway Capital as Partner, Sway Ventures.

Giovanni Agostinelli is listed by Sway Capital as Partner, Sway Capital.

Shelly Kapoor Collins is listed by Sway Capital as Managing Director, Sway Impact.

Marlon Evans is listed by Sway Capital as Managing Director, Sway Impact & Sway Studios.

Andrew Trapani is listed by Sway Capital as Managing Director, Sway Media.

Najib Khouri-Haddad is listed by Sway Capital as Managing Director, Sway Ventures.

Ken Denman is listed by Sway Capital as Managing Director, Sway Ventures.

Greg White is listed by Sway Capital as President & COO, Sway Capital.

Bill Malloy is listed by Sway Capital as Co-Founder, Sway Capital.

Brian Nugent is listed by Sway Capital as Co-Founder, Sway Capital.

Jonny P. leads defence and partnerships at RevEng.AI. He previously served as a Royal Engineer officer and worked as Head of Commercial at Egregious. He supports the company’s government and enterprise relationships. He uses an abbreviated surname in the company’s public welcome announcement.

Robert Marsal is Head of Engineering at RevEng.AI, building its AI and binary-analysis platform. His engineering leadership role is confirmed by the company and his own GitHub profile.

Henry Charlesworth leads machine learning research at RevEng.AI. He previously worked at Rowden Technologies and undertook postdoctoral deep reinforcement-learning research in Warwick’s WMG data science group.

James Patrick-Evans is founder and CEO of RevEng.AI, building AI models for reverse engineering and binary software analysis. He leads the company’s work on software supply-chain verification.

Jay Fuller co-founded Statespace with Wayne Mackey in2017. A neuroscientist, he helped build AI-powered training tools for perception, decision-making and motor coordination. NYU and Lux Capital identify him as co-founder. His research laboratory’s current alumni page lists him at Equinox; his Statespace founder relationship is historical and does not imply a current executive job.

Roberto Sanabria is a director of State Space Labs, Inc., confirmed in its April2026 SEC filing. He is a founding partner at Expa, whose own current team page identifies him and publishes his portrait. This investor and company director is distinct from similarly named actors and other professionals.

Member of Paradigm AI’s founding team. She announced joining the company in a public professional post accompanying its 2026 workflows launch.

Member of Paradigm AI’s founding team, identified in its August2025 company launch announcement. Specific executive title and current continuation were not independently disclosed.

Wayne Mackey is co-founder and CEO of Statespace, the developer of Aimlabs. He trained in neuroscience at New York University and applies cognitive science and machine learning to gaming performance. State Space Labs’ April2026 SEC filing confirms him as CEO and director.

Member of Paradigm AI’s founding team, identified in its August2025 company launch announcement. Specific executive title and current continuation were not independently disclosed.

Founder and CEO of Paradigm AI, developing agentic spreadsheets and structured-data research workflows. She studied computer science and entrepreneurship at the University of Pennsylvania and participated in Y Combinator Winter2024.

Advisory board member of Paradigm Health and former US Secretary of Veterans Affairs. David J. Shulkin is published by aMoon as External Adviser. Former US Secretary of Veterans Affairs and VA undersecretary for health, with healthcare leadership and public-service experience. This is an advisory or venture-partner affiliation; no employment or personal investment is inferred.

Retired US Army general and board member of Paradigm Health. He previously served as chief operating officer for Operation Warp Speed.

Board member of Paradigm Health and former CEO of Jefferson Health, bringing healthcare leadership experience to clinical research access.

Chief Operating Officer of Paradigm Health, overseeing sponsor, provider and internal operations. She previously served as COO of Vori Health and held leadership roles at Honor, Lyric and McKesson Technology. She studied at Harvard and Wharton. Distinct from the Michelle Lee associated with Lux Capital, Medra, AI Fund and SignalFire.

Chief Technology Officer of Paradigm Health, leading its clinical research platform development. He previously served as CTO of Orchard and vice president of engineering at Flatiron Health, and studied computer science at Georgetown. Elijah Meerson is published in the Irregular Expressions directory as Advisor / Limited partner (published directory affiliation). The directory summarizes this professional background: CTO @ Paradigm , CTO @ Orchard , VP Engineering @ Flatiron Health , Engineering Manager @ AppNexus. Outside-employer job titles are reproduced as directory background and are not independently asserted as current appointments.

Chief Financial Officer of Paradigm Health, responsible for financial strategy and operations. His previous roles included finance leadership at PRA Health Sciences, chief finance and operations officer at Science37 and CEO of Clinverse.

Chief Strategy and Growth Officer at Paradigm Health, working on wider access to clinical research. He previously co-founded Synapticure and chaired its advisory board. His Stanford biological sciences training specialized in neuroscience. Jonathan Hirsch — Synapticure publishes the following professional biography and affiliation: Jonathan Hirsch is a company founder, investor, and advisor at the intersection of healthcare, life sciences, and data. Jonathan founded Syapse in 2008, and during more than a decade of building the company, Jonathan defined and implemented a vision for transforming cancer care through precision medicine and real world evidence. Jonathan serves on the Advisory Boards of companies including Freenome, VizAI, and PaigeAI, and has helped shape the regulatory use of real world evidence through creating and serving as Principal Investigator for a Research Collaboration with the FDA. Jonathan has catalyzed national cancer data sharing networks, including serving on the White House Cancer Moonshot Data Sharing Working Group. As both an active investor and partner in venture funds, including the Kleiner Perkins seed fund and Rebel Fund, Jonathan has incubated and invested in dozens of companies at the intersection of healthcare and technology. The affiliation is scientific/strategic advice; outside employer and university titles remain external.

Founder and CEO of Paradigm Health, developing AI-enabled clinical research infrastructure. He previously served as ICON chief innovation officer and PRA Health Sciences chief scientific officer, with three decades of clinical research experience.

Joanna Soroka is listed in Relation’s board and observers group and works on healthcare and techbio investing at Hitachi Ventures. Hitachi’s own current profile calls her Investment Partner, while Relation’s directory retains Principal. Her background includes biochemistry, genetics and oncology research and healthcare strategy.

John Wesley is Investment Director at NVentures and is listed in Relation’s current board and observers group. NVentures is NVIDIA’s venture capital arm; his board-related affiliation does not imply a separate personal investment. John Wesley is publicly identified with NVentures as Senior Investment Director. His published biography describes investment and advisory work at Morgan Stanley, Bain, H.I.G. and Pequot, and operating finance roles at Omniox and as Dren Bio co-founder and CFO.

Jim Mellon is listed in Relation’s board and observers directory, which identifies his external affiliation as deputy-chair of Juvenescence. His inclusion does not establish a personal equity purchase in a specified Relation round.

Charles Roberts is co-founder and Chair of Relation, according to its current directory and 2024 company financing announcement. The company links his professional profile as Charles Powell Roberts; conflicting middle names in other issuer and legal records have not been used to infer a legal-directorship history.

Marc Wein serves on Relation’s Scientific Advisory Board. The company identifies him as Associate Professor of Medicine at Massachusetts General Hospital and Harvard Medical School.

John Whittaker serves on Relation’s Scientific Advisory Board. Relation identifies him as Director of the MRC Biostatistics Unit and Professor of Biostatistics at the University of Cambridge.

Jacob Corn serves on Relation’s Scientific Advisory Board. The company identifies him as Professor of Genome Biology at ETH Zurich and co-founder of Spotlight Therapeutics.

Alex Shalek serves on Relation’s Scientific Advisory Board. Relation identifies him as the J. W. Kieckhefer Professor in MIT’s Department of Chemistry, contributing expertise relevant to single-cell biology.

Caroline Uhler serves on Relation’s Scientific Advisory Board. The company identifies her as an MIT professor and co-director of the Eric and Wendy Schmidt Center at the Broad Institute.

Michael Bronstein serves on Relation’s Scientific Advisory Board. Relation identifies him as the DeepMind Professor of AI at the University of Oxford; his expertise connects machine learning and drug discovery. Michael Bronstein is CHIEF SCIENTIST IN RESIDENCE at Proxima Bio, formerly VantAI, contributing to its AI-enabled proximity-medicine discovery platform.

Matthew Page is VP, Data Science at Relation, contributing computational methods and biological data analysis to its drug-discovery platform.

Dave Powell is President of Drug Discovery at Relation, leading the drug-discovery work of its technology-enabled biopharmaceutical business. His original portrait and exact current title appear in the company’s executive directory.

Jake Taylor-King is Chief Innovation Officer and a co-founder of Relation. He is part of the company’s leadership and its published board and observers group, combining computational innovation with experimental drug discovery.

Benjamin Swerner is co-founder and Chief Operating Officer of Relation, overseeing operations at the AI-enabled drug-discovery company. The company and its transaction counsel identify him as a founder; its current directory also lists him in the board and observers group.

Rosie Rodriguez is President, Growth at Relation, working across the growth of its technology-enabled biopharmaceutical business. The company lists her among its current executive leadership.

Lindsay Edwards is Chief Technology Officer at Relation. Before joining in 2022, he led artificial-intelligence work in respiratory and immunology at AstraZeneca and earlier led AI and data-science groups at GSK.

David Roblin is Chief Executive Officer of Relation, leading AI-assisted drug discovery and development. He previously led European R&D at Pfizer and held senior scientific-translation and executive roles at the Francis Crick Institute. The company appointed him CEO in June 2022.

Tony Wood became GSK Chief Scientific Officer, Head of R&D and an Executive Committee member in August 2022. He joined GSK from Pfizer in 2017. His work spans medicinal chemistry, genetics, advanced technologies and strategic partnerships, with scientific fellowships including the Royal Society.

Deborah Waterhouse is CEO of ViiV Healthcare and GSK President, Global Health. She became ViiV CEO in April 2017 and joined GSK’s Executive Committee in January 2020. She joined GSK in 1996 and has held senior commercial roles across the US, Europe and Asia Pacific.

Phil Thomson is GSK President, Global Affairs, a role he took in 2017. He leads stakeholder engagement, reputation and policy strategy. He joined Glaxo Wellcome in 1996 and GSK’s Executive Committee in 2011.

Regis Simard is GSK President, Global Supply Chain and joined its Executive Committee in 2018. He leads medicine and vaccine manufacturing and supply, together with corporate quality and environmental health and safety responsibilities. He joined GSK in 2005 after roles at Sony, Konica Minolta and Tyco Healthcare.

David Redfern is GSK President Corporate Development, responsible for corporate development and strategic planning. He joined GSK in 1994 and its Executive Committee in 2008. He has chaired ViiV Healthcare’s board since 2011 and is a chartered accountant.

Shobie Ramakrishnan is GSK Chief Digital and Technology Officer and joined its Executive Committee in 2021. She leads technology and cybersecurity, having joined GSK in 2018. Her earlier technology leadership experience includes AstraZeneca, Salesforce, Genentech and Roche. Insight Partners source, reviewed October 8, 2026: Shobie Ramakrishnan is published in Insight Partners’ official External advisory directory; published employer title: GSK, Chief Digital & Technology Officer directory as GSK, Chief Digital & Technology Officer. The source publishes the name, exact affiliation and portrait but does not supply an expanded career or education biography. External employer responsibilities are source-published context, not an Insight employee or personal-investment claim.

Roanne Parry became GSK Chief People Officer and joined its Executive Committee in May 2026. She leads the company’s people and culture strategy. She previously served as CSL chief human resources officer and had earlier spent 22 years in GSK human resources leadership.

Nina Mojas is GSK President, Global Product Strategy and joined its Executive Committee in 2026. She oversees global commercial strategy, lifecycle management and market access. She joined GSK in 2020 and previously held senior oncology roles at AstraZeneca and an investor-relations role at Roche.

Maya Martinez-Davis is GSK President, US and joined its Executive Committee in 2026. She joined GSK in 2019 following biopharma and oncology leadership roles at Merck KGaA and Pfizer. She is also an independent director of Perspective Therapeutics.

Mondher Mahjoubi is GSK Chief Patient Officer and joined its Executive Committee in 2026. He leads global medical strategy, evidence generation and scientific engagement. He joined GSK in 2024 after serving as Innate Pharma CEO and holding leadership roles at AstraZeneca, Genentech, Roche and Sanofi.

James Ford is GSK Senior Vice President and Group General Counsel, Legal and Compliance. He joined GSK in 1995 and its Executive Committee in 2018, later taking on compliance, security and investigations responsibilities. He previously practiced law at Clifford Chance and DLA.

Mike Crichton is GSK President, International and joined its Executive Committee in 2026. He leads commercial growth outside the US and Europe, including China and Japan. He joined GSK in 2018 following senior roles at Novartis, AstraZeneca and Roche.

Lynn Baxter is GSK President, Europe and joined its Executive Committee in 2026. She leads commercial performance and strategy across European markets. She joined GSK in 2009 and has held senior roles in vaccines and at ViiV Healthcare, following commercial positions at Roche and Merck.

Vishal Sikka is a GSK independent non-executive director appointed in July 2022. He founded Vianai Systems and brings artificial intelligence, machine learning and cybersecurity expertise. He previously served as Infosys CEO and in senior technology and executive-board roles at SAP.

Gavin Screaton is a GSK independent non-executive director appointed in May 2025. His scientific and clinical expertise spans immunology, infectious disease and experimental medicine. He previously served as chair of medicine at Imperial College’s Hammersmith Hospital. Gavin Screaton is named by the University of Oxford as Head of Medical Sciences Division in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks. Oxford’s current Medical Sciences leadership directory independently confirms the headship alongside the separate GSK non-executive directorship; immunology research remains an academic role, not a personal company investment.

Jeannie Lee is a GSK independent non-executive director and a scientific and medical expert. Her scientific work concerns epigenetics and gene regulation, with expertise in RNA biology and approaches to understanding genetic disease.

Roy Jakobs joined GSK as an independent non-executive director on 13 July 2026. He has served as CEO of Royal Philips since 2022, following international leadership roles at Philips, Shell and Elsevier. He brings experience in healthcare technologies including imaging and patient monitoring.

Harry Dietz is a GSK independent non-executive director and scientific and medical expert appointed in January 2022. A physician-scientist specializing in human genetics and heritable connective-tissue disorders, he is known for research on Marfan syndrome and disease-modifying approaches in fibrosis and neurodegeneration.

Wendy Becker is a GSK independent non-executive director appointed in October 2023. Her leadership experience spans technology, consumer businesses and healthcare, including serving as Jack Wills CEO, Vodafone chief marketing officer and a McKinsey partner.

Anne Beal is a physician and entrepreneur serving as a GSK independent non-executive director since May 2021. Her expertise includes patient advocacy, health policy and research access. She previously held leadership roles at the Patient-Centered Outcomes Research Institute and Sanofi and worked at Harvard Medical School and Massachusetts General Hospital.

Hal Barron is a non-executive director of GSK, having transitioned from Chief Scientific Officer and President of R&D in August 2022. He joined its board in 2018 and previously led research and development at Calico. His work emphasizes genetics and technology in drug discovery.

Charles Bancroft is GSK’s Senior Independent Non-Executive Director, having joined its board in May 2020. He retired from Bristol Myers Squibb in 2020 after a career spanning financial, commercial, integration and strategy leadership, including serving as chief financial officer.

Elizabeth McKee Anderson is a GSK independent non-executive director appointed in September 2022. Her commercial biopharmaceutical experience includes leadership in infectious diseases, vaccines, immunology and oncology at Janssen and Wyeth. She has engineering and business qualifications.

Julie Brown became GSK Chief Financial Officer and a board director on 1 May 2023. She previously held senior finance and operating positions at Burberry, Smith & Nephew and AstraZeneca and served on Roche’s board. She is a chartered accountant and tax professional.

Luke Miels became GSK Chief Executive Officer and a board director on 1 January 2026, succeeding Emma Walmsley. He joined GSK as Chief Commercial Officer in 2017 after executive roles at AstraZeneca and Roche. He studied biology at Flinders University and earned an MBA at Macquarie University.

Jonathan Symonds has chaired GSK since September 2019. His background includes chief financial officer positions at Novartis and AstraZeneca, senior roles at Goldman Sachs and KPMG, and board leadership at HSBC. He brings finance, governance and life-sciences experience.

Jean-Claude Dardelet serves as Supervisory Board Member — Representative of Cities at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Pascal Feillard serves as Supervisory Board Member — Representative of Industry at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Lenka Scholzova serves as Supervisory Board Member — Representative of Universities at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Zuzana Pickóva serves as Supervisory Board Member — Independent Representative at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Mika Rytkönen serves as Supervisory Board Member — Independent Representative at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Lina Konstantinopoulou serves as Supervisory Board Member — Independent Representative at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Jan Van Den Oetelaar serves as Independent Supervisory Board Chair at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Silvia Simonelli serves as Head of Finance at EIT Urban Mobility. She leads finance planning, budgets, reporting and analysis, including controlling and reporting for EU-funded programmes. She holds a business administration master’s degree from ESADE.

Daniel Moix serves as Head of IT at EIT Urban Mobility. He leads IT applications, infrastructure and services, with experience managing regional technology services. He holds an MBA from Trinity College Dublin and telecommunications and telematics engineering degrees.

Elisa Kerschbaumer serves as Head of PMO at EIT Urban Mobility. She joined the Project Management Office in late 2022 and has led it since early 2026. Her work covers grants management, audits and compliance for European-funded programmes.

Lluis Puerto serves as RIS and EIT Community Director at EIT Urban Mobility. His experience covers safe and sustainable transport, intelligent transport systems, public policy and go-to-market consulting. He formerly served on the boards of ERTICO and EuroRAP.

Willem Frederik Metzelaar serves as Regional Director (West) | Interim Regional Director (North) at EIT Urban Mobility. His background includes commercial leadership in energy utilities, founding data analytics companies, investing and work at EIT Digital.

Judith O'Meara serves as Regional Director at EIT Urban Mobility. She has worked on European research and innovation funding, consortium development and commercialization of research, including at the Max Planck Society and Technical University of Munich.

Martí Massot serves as Regional Director at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Traian Urban serves as Regional Director at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Jaume Campmany serves as Legal Director at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Sandrine Martin Tran Ba Huy serves as People & Culture Director at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Bernadette Bergsma serves as Communications & EU Affairs Director at EIT Urban Mobility. The role is published in the initiative’s current leadership and governance directory.

Maria Paula Caycedo serves as Business Development Director at EIT Urban Mobility. Her background spans aeronautics, automotive and consulting, with experience in product development, sales, business expansion and intelligent transport systems.

Adriana Diaz serves as Innovation and Strategy Director at EIT Urban Mobility. Her work covers technology policy and innovation, including autonomous mobility deployment. She holds an engineering and policy analysis MSc and a doctorate in economics of innovation.

Martin Vendel serves as Academy Director at EIT Urban Mobility. He combines academic research and teaching with corporate and startup leadership, focusing on strategy, business development and technology-driven industry transformation.

Philipp Schöllauf is nyra health's co-founder and chief scientific officer. A neurologist with experience in stroke care and rehabilitation, he leads clinical research and the therapy framework supporting the company's products. He is also a registered managing director.

Miguel Ángel Martínez serves as Head of Cabinet at EIT Urban Mobility. His background spans climate science, innovation management and science policy at the University of Southampton, the UK government and the European Commission. He holds environmental sciences degrees from Universitat Autònoma de Barcelona.

Mario Zusag is co-founder and CTO of nyra health. His background includes computer science at TU Vienna, machine learning at Imperial College London and research at Google Brain and IBM Research. He leads the company's multimodal neurorehabilitation technology and is a registered managing director.

Moritz Schöllauf is nyra health's co-founder and CEO. A lawyer with expertise in regulation, data protection and medical-device compliance, he leads strategy, partnerships and regulatory operations. He is also a registered managing director of the company.

Francisco Ibáñez serves as Chief Financial Officer at EIT Urban Mobility. His background includes consulting at Accenture and McKinsey, strategic planning and management at CEMEX, and business development and fundraising support at EIT Digital. He holds a Harvard MBA and a mechanical engineering degree from the University of Texas at Austin.

Marc Rozendal serves as Chief Executive Officer at EIT Urban Mobility. He became CEO effective 1 April 2025 after serving as UK managing director at Ola and CEO of Cab Guru. His experience spans transport technology, public transport and business transformation.

Julia Hillebrand is Managing Director and co-owner of EVER Pharma and a member of its Executive Board. She joined the company in 2013 as Head of Corporate Development and has led its Neurology business unit since 2016. She holds a medical doctorate from the Medical University of Vienna. Nyra health’s CEO publicly acknowledges her support, while its registered equity investor is the separate HIL-INVENT family investment vehicle. The official Austrian register also lists her as a Managing Director of HIL-INVENT Ges.m.b.H., the separately registered Hillebrand family investment vehicle.

Georges Kahwati is Chief Executive Officer of EVER Neuro Pharma, EVER Valinject and EVER Pharma Jena. Before joining the EVER Pharma Group, he worked at Sandoz International as Global Head of Commercial Operations for oncology injectables and General Manager of its Unterach site. He previously led specialty injectables at EBEWE Pharma and holds a commerce degree from McGill University and an MBA from INSEAD.

Friedrich Hillebrand is Chairman and owner of the EVER Pharma Group. He led EBEWE Pharma as CEO until 2009 and has worked across pharmaceutical development, manufacturing and commercialization for more than four decades. He holds a doctorate in chemical engineering from the University of Vienna. The official Austrian register also lists him as a Managing Director of HIL-INVENT Ges.m.b.H., the separately registered Hillebrand family investment vehicle.

Raj Shah is a director of the NATO Innovation Fund, managing partner of Shield Capital, and co-founder and chair of cyber-insurance company Resilience. He previously led the Pentagon’s Defense Innovation Unit Experimental and Morta Security. He is an F-16 pilot and studied at Princeton and Wharton.

Kusti Salm is a director of the NATO Innovation Fund and CEO of Frankenburg Technologies. He previously served as permanent secretary of Estonia’s defence ministry and led the Estonian Centre for Defence Investment.

Ebru Dorman is a director of the NATO Innovation Fund. Her experience includes HSBC Bank Türkiye, Borusan Ventures, Morgan Stanley Strategic Ventures and Orange Ventures. She earned degrees at Harvard Business School and UC Berkeley. Borusan Ventures publishes Ebru Dorman as an Advisor on its Investment Committee. Its biography describes NATO Innovation Fund and independent corporate board responsibilities, earlier MV Holding and StartersHub leadership, and investment and telecom experience. This committee appointment does not establish a personal cash investment in Borusan portfolio companies.

Prince Constantijn of the Netherlands is a director of the NATO Innovation Fund and co-founder and special envoy of Techleap. His prior roles include European Commission digital-policy leadership and work at RAND.

Roberto Cingolani is a director of the NATO Innovation Fund and CEO and General Manager of Leonardo. He previously served as Italy’s Minister for Ecological Transition and founded the Italian Institute of Technology.

Tarja Jaakkola is a board observer at the NATO Innovation Fund and NATO’s Assistant Secretary General for Defence Industry, Innovation and Armaments. She previously held senior positions in Finland’s defence ministry and the European Defence Agency.

Karl-Christian Agerup is Vice Chair of the NATO Innovation Fund’s board. He is a global partner at Antler and previously co-founded Northzone Ventures and led Oslotech and Hugin.

Fiona Murray chairs the NATO Innovation Fund’s board. She is an MIT Sloan professor and Associate Dean of Innovation, and directs MIT’s Office of Innovation. Her research and advisory work concerns science, technology and innovation policy.

Suzana Ielcean is an Executive Assistant and London Office Manager at the NATO Innovation Fund. Her earlier executive-support experience includes Facebook, Salesforce and Pinterest.

Marrit Leenstra is an Executive Assistant and Amsterdam Office Manager at the NATO Innovation Fund. She previously competed in three Olympic Games in volleyball and beach volleyball.

Mariana Occidente Lupo is an Executive Assistant at the NATO Innovation Fund, supporting its board and senior leadership. She previously assisted the general counsel of Walgreens Boots Alliance and Italy’s defence attaché in London.

Mary De Albergaria is a Platforms and Events Associate at the NATO Innovation Fund.

Veronika Bartakova manages limited-partner and government relationships at the NATO Innovation Fund.

Lennart Velten is an Associate at the NATO Innovation Fund.

David Ordonez is a Senior Associate at the NATO Innovation Fund, working on deep technology investments.

Trisha Saxena is a Senior Associate at the NATO Innovation Fund, researching and supporting deep technology investments.

Joel Noutere is an Adoption Associate at the NATO Innovation Fund.

Lauren Reade leads the NATO Innovation Fund’s adoption platform.

Alex Kugajevsky is an Adoption Principal at the NATO Innovation Fund, supporting the use of portfolio companies’ technologies by customers across the Alliance.

Amalia Kontesi is Chief Communications and Marketing Officer at the NATO Innovation Fund, supporting investment communications and stakeholder relations. Her prior experience includes Google’s EMEA social-impact communications and sustainability communications at JPMorgan Chase.

Susan Wilson is Chief Human Resources Officer at the NATO Innovation Fund. She previously led HR at Mollie and held regional HR leadership roles at Uber, with experience in scaling businesses and organisational change.

Helen Draijer is Chief Financial Officer at the NATO Innovation Fund, overseeing finance and risk. She previously held CFO positions at Avedon Capital Partners and Lagardère Travel Retail Netherlands. She studied accountancy and control at the University of Amsterdam.

John Ridge is Chief Adoption Officer at the NATO Innovation Fund, helping portfolio technologies reach government and industry customers. His prior career spans the British Army and UK government, including operational command and defence intelligence.

Kate O’Brien supports the NATO Innovation Fund’s board and its coordination with senior leadership. A qualified lawyer, she previously served as general counsel and company secretary at Oxford Science Enterprises and advised Lansdowne Partners on private technology investments.

Ari Kristinn Jónsson is President of the NATO Innovation Fund. He previously led Videntifier and a university in Iceland and worked for a decade at NASA. He earned an artificial intelligence doctorate at Stanford in 1997.

Patrick Schneider-Sikorsky is a Partner at the NATO Innovation Fund, leading ecosystem development and Central and Eastern European coverage. He previously co-founded Beast Ventures and invested in AI, autonomy, biotechnology and other deep technologies. He studied at Oxford, the University of London and MIT Sloan.

Sander Verbrugge is a Partner at the NATO Innovation Fund. His experience includes Innovation Industries, NXP Semiconductors and Roland Berger. He holds a TU Delft master’s degree and a molecular biophysics doctorate from Vrije Universiteit Amsterdam.

Erin Hallock is a Partner at the NATO Innovation Fund, working on commercial adoption of deep technologies. She previously served as a managing partner at bp Ventures and held leadership positions at BGF and Barclays.

Ulrich Quay is a Partner at the NATO Innovation Fund. He previously built and led BMW i Ventures, investing across mobility, energy, industrial automation and AI. He holds a doctorate in law from the University of Freiburg.

Taras Lutsiv is an Investment Associate at D3 (Dare to Defend Democracy), an early-stage investor in AI, autonomy, robotics and other deep technologies for national security. The current official D3 directory lists this investment team role.

Elya Chiechienieva is a Co-Founder and Partner at D3 (Dare to Defend Democracy), an early-stage investor in AI, autonomy, robotics and other deep technologies for national security. Denmark’s EIFO identifies this person as one of D3’s three founders in summer 2023.

Anton Verkhovodov is a Co-Founder and Partner at D3 (Dare to Defend Democracy), an early-stage investor in AI, autonomy, robotics and other deep technologies for national security. Denmark’s EIFO identifies this person as one of D3’s three founders in summer 2023.

Eveline Buchatskiy is a Co-Founder and Managing Partner at D3 (Dare to Defend Democracy), an early-stage investor in AI, autonomy, robotics and other deep technologies for national security. Denmark’s EIFO identifies this person as one of D3’s three founders in summer 2023.

Tessa Bottenschein is an Investment Associate at Armira Growth, where her published alumni biography records her joining in 2024 after working at Bain & Company from 2022 to 2024. She studied business administration at St. Gallen and international finance at Nova School of Business and Economics. Her own 2026 investment announcement discusses Armira Growth’s lead investment in AI neurorehabilitation company nyra health.

Sebastian Johnston is a Venture Partner at Armira Growth and a founding partner of La Famiglia. He is an entrepreneur and angel investor and serves as president of Enactus Germany. His personal backing of companies is distinct from institutional Armira Growth investment participation.

Florian Tappeiner is a founding partner and Managing Partner of Armira Growth, joining in October 2021. He previously co-led NuCom Group and worked in strategic investments at ProSiebenSat.1, H.I.G. Capital and Allianz. He studied industrial engineering at TU Ilmenau and earned a doctorate in entrepreneurial finance at TU Munich.

Christian Figge co-leads Armira’s Growth strategy as Managing Partner. He previously spent more than a decade at General Atlantic, ultimately as Managing Director, and earlier worked at BC Partners and L.E.K. Consulting. He holds a PhD from the Technical University of Munich, an MA in Economics from LMU Munich and a BA in Economics and Management from Oxford.

Max Enders heads Business Development and Government Affairs at TYTAN Technologies and is the company's named press contact.

Chris Badia joined TYTAN Technologies' board in 2026. The former German Air Force general served as NATO Deputy Supreme Allied Commander Transformation from July 2022 to July 2025.

Tahsin Kart joined TYTAN Technologies as co-CEO in 2026 to lead industrial scaling. He formerly served as CTO of CycloTech and lead engineer at Roketsan Missiles.

Batuhan Yumurtacı is CTO and co-founder of TYTAN Technologies and a Technical University of Munich alumnus. He co-founded the company with Balázs Nagy in 2023.

Balázs Nagy is CEO and co-founder of TYTAN Technologies. He studied energy engineering in Budapest and aerospace engineering at the Technical University of Munich, where he founded the HORYZN student drone initiative.

Chloe Legge serves as Marketing Manager at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Nina Litman-Roventa serves as Investment Manager at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Eva Frey serves as Executive Assistant & Office Manager at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Jaisal Singh Shergill serves as Fund Operations Analyst at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Francesco Pomponi serves as Head of Carbon Math at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Paul Eisenberg serves as Investment Manager at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Paola Brenni serves as Investment Associate at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Oliver Schwarzer serves as Partner & CFO at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Fernanda Bartels serves as Marketing Director at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Christian Guba serves as Principal at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Moritz Kötter serves as Investment Associate at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Joern-Carlos Kuntze serves as Partner at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Tess Dury serves as Director of Impact & ESG at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Sebastian Heitmann serves as Partner at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Torben Schreiter serves as Partner at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Carlota Ochoa Neven Du Mont serves as Principal at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Yair Reem serves as Partner at Extantia, a Berlin-based climate technology venture investor. This current role is published in the firm’s team directory.

Andreas Lächelt is Head of Group Accounting at NexDash. Entrepreneur and experienced accounting leader. Leads group accounting, consolidation and financial reporting at NexDash.

Beacon Partners adviser. Beacon’s published advisory directory describes Suzanne Behrens as Former CMO, Granicus. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Ryan Pinder as Former Attorney General, Bahamas. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Doug Rogers as VP, Lumeris. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Jake Bornstein as Co-Founder, Studio Metis. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Michael Tully as Founder & CEO, Journey Holdings. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Anil Varanasi as Founder & CEO, Meter. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Suze Skop as Sr. Director, Agencies, Instacart. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Charlie Fang as Product, Surge AI; prev. Hertz. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Will Simmons as Product, Ramp. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Will Petrie as CFO, Ramp. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Nikhil Shanbang as VP Competition Law, Meta. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Andrew Nodes as VP Supply Chain, Instacart. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Morgan Fong as General Counsel, Instacart. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Max Schnoedl as Chair, GovPilot; prev. COO Accela. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Mary Miller as Founder, Ciconia; prev. Amazon. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Arnaud Ferreri as CTO, Headway. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Euan Blair as Founder & CEO, Multiverse. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Farhan Thawar as VP & Head of Eng, Shopify. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Dani Dudeck as CCO, Netflix. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Bob Hardester as Former CIO, Schnucks Markets. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes James Dyett as Former Head of Enterprise Sales, OpenAI. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Laura Chmar as Former VP Medicare, Aledade. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Karney Li as Former Chief Architect, Wealthsimple. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Nikila Srinivasan as Former VP Product Management, Meta. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Sagar Sanghavi as Former CFO Abridge. This is an external advisory relationship with Beacon.

Beacon Partners adviser. Beacon’s published advisory directory describes Rob Crisci as Former CFO Lineage Logistics. This is an external advisory relationship with Beacon.

Vice President of AI Research at Beacon following its September 2026 acquisition of Haize Labs. Leads initiatives to deploy reliable AI across Beacon’s software businesses.

CTO of Beacon, appointed in June 2026. Previously AngelList CTO and a senior engineering leader at Coinbase.

COO and CPO of Beacon, appointed in June 2026 to scale its AI operating platform. Previously CTO of Instacart and Superhuman.

Founder and CEO of Beacon, a permanent holding company that acquires essential software businesses and modernizes them with AI and shared operating resources. Former President of Instacart and partner at D1 Capital.

Co-founder and CTO of Metaview, the AI recruiting platform he co-founded in 2018 with Siadhal Magos.

Co-founder and CEO of Metaview, the AI recruiting platform he co-founded in 2018 after building teams at Uber and Palantir with Shahriar Tajbakhsh.

Tom Greever is a design leader known for helping teams turn strong design instincts into cohesive, scalable systems. He joined CoLab drawn by its commitment to keeping its engineering platform human-first while integrating the best of what AI has to offer.

Jessie Wheeler brings her expertise as a proven scale-up operator to CoLab, having helped lead Own Company to a $2B+ exit before driving strategic initiatives at Salesforce. She joins at a key inflection point, bringing the experience and urgency needed to turn momentum into durable, repeatable scale.

Sydney Strader brings extensive experience building and leading Customer Success organizations at scaling SaaS companies. Before joining CoLab, she spent three years at InVision, rising from Customer Success Manager to Vice President as the company scaled to $100M in ARR. She then served as SVP of Customer Success at Catalyst Software, leading the team through the company’s successful acquisition.

Taylor Jones brings more than 15 years of experience leading sales and business development teams in high-growth software companies. Before joining CoLab, she held sales and business development leadership roles at Salesforce and helped scale revenue at Zip, a leading intake-to-procure platform, from early growth through the scale-up phase.

Jake Kornreich brings over a decade of leadership in high-growth B2B SaaS to CoLab. Most recently CFO at Own Company (formerly OwnBackup), he helped scale the business to 900+ employees across seven countries, raised several hundred million in capital, and led key operations as the company grew—culminating in a $2.2B acquisition by Salesforce.

With nearly three decades of experience in cybersecurity, IT, cloud, and software development—including over 15 years in leadership—Robert Percy brings deep expertise to protecting what matters most to CoLab’s customers: their product designs and intellectual property. As CIO, he led the company to achieve and maintain SOC 2 Type 2, ISO 27001, and TISAX AL3 certifications, ensuring the highest standards of security and trust.

MJ Smith brings a mix of manufacturing and SaaS experience to her role as CoLab’s CMO. She started her career as a hardware product manager, working directly with engineering teams across several manufacturing businesses within FTSE 100 Halma plc, where she became the youngest executive director of a Halma operating company at age 24.

Taylor Young has been part of CoLab’s journey from the earliest days, helping shape the company into what it is today. She built CoLab’s business development, marketing, and customer success functions from zero to one and has worked directly with hundreds of engineering teams across industries—from automotive to aerospace and defense.

Jeremy Andrews is a mechanical engineer turned technologist who co-founded CoLab after seeing firsthand how slow and fragmented design collaboration can be. While working at Tesla and General Dynamics, he led DFM reviews that could take up to eight weeks on a single part—an experience that sparked his conviction that engineering teams needed a better way to make design decisions.

Adam Keating is a mechanical engineer turned founder who started CoLab after realizing how much innovation is lost when engineers spend more time managing files and feedback than solving problems. At ExxonMobil and RefleXion Medical, he saw firsthand how these inefficiencies slow down even the most advanced teams. Adam co-founded CoLab to help organizations make better design decisions, faster—accelerating how complex products come to life.

Sapphire Ventures partner who joined Blue J’s board with its August 2025 Series D financing.

Blue J co-founder and University of Toronto law and economics scholar.

Blue J co-founder and University of Toronto law professor researching artificial intelligence, law and economics.

Product executive at Blue J; previously Chief Product Officer at DocuSign and founder of Yield Software.

Technology executive and co-founder of Blue J with software architecture and delivery experience.

Leads financial strategy at Blue J; previously CFO at Miovision with experience at PointClickCare and Ataccama.

Leads Blue J go-to-market execution; previously Chief Operating and Customer Officer at Vena Solutions.

Leads Blue J go-to-market operations and global commercial expansion.

Leads people and culture, talent and organizational operations at Blue J.

Law professor and Blue J legal innovation strategist; formerly its Vice President of Legal Research.

Leads customer onboarding, adoption, growth and retention at Blue J.

Tax law scholar and entrepreneur who co-founded Blue J in 2015; holds the Osler Chair in Business Law at the University of Toronto.

Leads advertising technologies at StackAdapt.

Leads inventory development at StackAdapt.

Leads product marketing at StackAdapt.

Leads StackAdapt’s global finance and accounting functions; previously CFO at Kinaxis and a finance executive at Shopify.

Leads StackAdapt client services; promoted from SVP, Global Client Services in October 2026.

Leads StackAdapt’s legal function; promoted from General Counsel in October 2026.

Chief Revenue Officer at StackAdapt.

Chief Marketing Officer at StackAdapt.

Co-founded StackAdapt with Vitaly Pecherskiy and Yang Han.

StackAdapt co-founder and CTO; leads technology for its AI advertising platform.

Co-founder and CEO of StackAdapt, which develops an AI advertising and marketing platform.

Clinical professor at Stanford and director of medical dermatology at Stanford Health Care.

Professor of public health and clinical epidemiology at Exeter, researching diagnostic test evaluation.

Consultant dermatologist at Chelsea and Westminster Hospital working on teledermatology and skin surgery.

Consultant dermatologist with interests in skin cancer and immunosuppressed patients.

Public health physician and rural general practitioner with medical leadership experience.

Software entrepreneur and business angel; founded Media Net Software and co-founded BuyVIP.

Healthcare chair and adviser; previously chaired UCLPartners and two NHS trusts.

Marketing executive with experience scaling consumer technology and health technology brands.

Clinical research specialist with a PhD in medical microbiology.

Medical device quality and regulatory affairs specialist.

Software engineer and technical architect with medical technology and startup experience.

Practicing GP working in AI and digital health.

Chartered accountant with finance and operations experience in startups and regulated lending.

Computer vision and machine learning researcher with a computer science PhD from Bristol.

Founded Skin Analytics in 2012; previously a GSMA director supporting mobile banking.

Gabriel Grunberg is Head of Business Intelligence & Analytics at NexDash. Former VP Planning & Analysis at Grover. Leads business intelligence and performance analytics at NexDash.

Gergö Birkas is M&A Origination Lead, DACH at NexDash. 15 years in freight forwarding and fleet advisory with a deep network of carrier owners across DACH. Leads M&A origination at NexDash.

Elisa Nenning is Director Communications & Founder Associate at NexDash. Former Global Communications Director at Grover and ex-Sony Pictures. Leads brand, communications and executive positioning at NexDash.

Parth Patne is Lead AI Engineer at NexDash. M.Sc. in AI Engineering. Building NexOS from the ground up. Multiple published research papers on AI.

Berit Inga Stranz is VP Sales & Strategic Partnerships at NexDash. Former VP Business Development & Strategic Partnerships at Grover. Leads shipper relationships and strategic partnerships at NexDash.

Esteban Escalante is VP Operations & Electrification at NexDash. Former CCO at Grover and a key driver of its growth from €10M to €300M ARR. Leads NexDash's electrification and energy transition.

Franck Pascault is Chief Financial Officer at NexDash. Former CFO & Managing Director at Tourlane and ex-Goldman Sachs investment banker. Leads NexDash's finance, capital strategy and M&A.

Karsten Sachsenröder is Chief Operating Officer at NexDash. Former CxO at DB Schenker with 30+ years of experience building and operating transport and logistics businesses. Leads NexDash's carrier operations and integration.

Michael Cassau is Founder & CEO at NexDash. Founder of Grover, scaling the company from zero to $300M ARR and a $1B+ valuation. Now applying the same technology, assets and capital playbook to build Europe's first neo-carrier.

Zihao Qi co-authored Mabyduck’s January 2026 evaluation of interactive AI avatars, with the company identifying the role as Research Intern. The appointment dates and continued status after that publication are undisclosed. This record concerns the Mabyduck evaluation researcher and is distinct from researchers with the same name in physics, mass spectrometry and electrical engineering.

Ivan Gerov is identified as a Software Engineer by Mabyduck in its January 2026 interactive-avatar evaluation publication. His professional profile confirms Mabyduck and an Aston University background including cognitive psychology and an EEG-based visual-attention study. An authentic portrait was not recovered from accessible primary sources.

William Blackie is Staff Engineer at Mabyduck, building full-stack products with Python and TypeScript. His personal website lists the role from April 2025 onward and earlier work at Torchbox, Developerfy and a Google DeepMind contract. He maintains the Mabyduck-supported django-vrt visual-regression project.

Till Aczél is a Research Scientist at Mabyduck, working on perceptual quality assessment of AI-generated images. His own website records a research internship beginning January 2026 and a full-time research-scientist appointment on July 1, 2026. He also researches neural compression and efficient deep learning as a PhD researcher at ETH Zurich with Roger Wattenhofer.

Lucas Theis founded Mabyduck, a human-feedback evaluation platform for generative AI. He previously researched neural compression at Google Brain and DeepMind and worked at Twitter following its acquisition of Magic Pony Technology. His PhD at the University of Tübingen and Max Planck Research School focused on probabilistic generative image models. Companies House identifies him as Lucas Marvin Theis, director since July 2024.

Christoph Wintersteiger is a senior computer scientist at Imandra. His research covers software verification, decision procedures and automated reasoning, following doctoral work at ETH Zurich.

Makar Valentinov works in research and engineering at Imandra. His company biography describes a Cambridge physics background and interests in computational physics, neural networks and financial technology.

Cruise Song is listed as an Imandra research intern. His work connects automated reasoning and interactive theorem proving, including Lean, with a research affiliation at Georgia Institute of Technology.

Brian Schwieger is an Imandra strategic advisor with experience in financial-market leadership and governance. He previously led equity trading at LSEG and held roles at Bank of America Merrill Lynch and Morgan Stanley.

Stephanie Radics manages operations at Imandra, covering team logistics, finance and employee relations. Her earlier operations work was in hospitality and property management.

Sebastian P is listed as a principal engineer at Imandra, with experience in cloud development and typed functional languages. His published company profile identifies him by a surname initial rather than a full surname.

Eric Meinhardt works in research and engineering at Imandra. His interests include typed functional programming, domain-specific languages, automata and reasoning about state machines; he holds a linguistics PhD.

Hongyu Lin works in research and engineering at Imandra, focusing on machine learning for financial time series. He studied financial mathematics at Central University of Finance and Economics and the University of Leeds.

Kostya Kanishev, also identified as Konstantin in his company biography, works in AI research and engineering at Imandra. His background combines particle-physics research, work at CERN and computer science.

Elijah Kagan is Imandra's head of design. His experience spans agency and independent design, creative development and work for global businesses and institutions.

Andrey Ignatovich works in senior research and engineering at Imandra. His background includes enterprise software development at ADP/CDK and computer-science and astronomy studies at Saint Petersburg State University.

Bence Graics works in Imandra research and engineering, applying formal methods to model-based systems engineering and SysML v2. He developed the Gamma Statechart Composition Framework and earned a PhD in Budapest.

Remi Desmartin is listed as a research fellow at Imandra. His research focuses on neural-network verification, including work applying Imandra to that problem at Heriot-Watt University.

Samer Abdallah works in research and engineering at Imandra. His background spans music informatics, Bayesian modelling, functional and logic programming, with research experience at King's College London and Queen Mary University of London.

Paul Brennan is chief strategy officer at Imandra. His background includes product and strategy in financial markets and serving as COO of Goldman Sachs' regulated trading venue. He is distinct from the Curve Therapeutics scientific advisor with the same name.

Zehra Akbar is Imandra's chief operating officer. She previously helped establish Boeing and SparkCognition's SkyGrid joint venture and led its strategy function, following roles at SparkCognition, Deloitte and Accenture.

Grant Passmore is Imandra's co-founder and co-CEO, leading its automated reasoning technology. His research covers formal verification, symbolic AI and nonlinear theorem proving. He earned a PhD at Edinburgh.

Denis Ignatovich co-founded Imandra and serves as co-CEO. He previously led Deutsche Bank London's central risk trading desk and brings experience in quantitative finance and trading-system design.

Robert Quick is co-founder and COO of trawa, responsible for operations and finance at its AI-enabled energy supplier.

Max Lüddemann is co-founder and CTO of trawa, responsible for software development and data analysis for its AI-enabled energy platform.

David Budde is co-founder and CEO of trawa, responsible for product development, sales and partnerships at the Berlin AI-enabled energy supplier.

Jamie Kasuboski serves on Character Biosciences’ board; the company lists their affiliation as Luma Group.

Luma Group co-founder and partner with a scientific research background in genomics, neuroscience and cancer biology; serves on the Aeovian Pharmaceuticals board.

David Rosskamp is the founding partner of Magnetic Capital, a European venture capital firm investing in technology for critical industries. He is identified as its Managing Partner in the 2024 STARTUPLAND speaker directory and as Founding Partner in NaroIQ’s June 2025 financing announcement. His work covers infrastructure, security, financial technology and industrial technology.

Technology executive and former Databricks EMEA CTO, leading PhysicsX technology and platform development.

AI and genomics executive who previously led Genomics England and served as COO of QuantumBlack. At PhysicsX, he leads commercial expansion and operational scale.

Strategy and Programs Manager at PhysicsX, as listed in the company team directory.

Adrian is a Director of Research in machine learning at the University of Cambridge and Head of Safe and Ethical AI at the Alan Turing Institute.

Talia is a clinician leader and executive advisor at the intersection of business and healthcare, with responsibility for the strategic and day-to-day success of major corporate engagements. She is Physician Lead of Advisory Services at Cleveland Clinic based in Canada, holding P&L responsibility and advising cross-industry executives. She is a member of the Senior Leadership Team which includes developing annual strategic and financial planning, succession planning, setting of corporate policy, talent management, risk management as well as monitoring of corporate performance against business plans and KPIs.

Tap is a seasoned leader with 25+ years of experience leading strategy, technology, business and corporate development at worldwide technology companies ranging from start ups to Fortune 100. He is passionate about developing and leading cross-functional teams to achieve bold goals on a global scale.

Air Chief Marshal Sir Mike Wigston was Chief of the Air Staff from 2019-2023, the 4-star commander and head of the Royal Air Force. As principal air and space advisor to the Prime Minister, Secretary of State for Defence, and the Chief of Defence Staff, he was one of the youngest ever to hold the role.

Richard Sutton pioneered one of the most powerful techniques of the modern AI revolution: Reinforcement Learning.

Sendhil is Professor of Economics and Peter de Florez Professor of EECS (Electrical Engineering & Computer Science) at MIT. His current research uses machine learning to understand complex problems in human behavior, social policy, and especially medicine, where computational techniques have the potential to uncover biomedical insights from large-scale health data. Sendhil is cofounder of Nightingale, the computational medicine initiative, Pique, an app that changes how people read books and learn, and Dandelion, a company that catalyzes AI in healthcare.

Niamh is an AI Research Scientist based in Silicon Valley. As a researcher and early access partner, she helped launch multimodal foundation models from OpenAI and DeepMind and open LLMs from Meta-Llama and Mistral. Alongside, Niamh is a trusted advisor to governments, think-tanks and international agencies on emergent technologies.

Emily is an Internal Operations Lead, supporting the leadership team and office operations in the UK. Prior to joining Intrepid, she served as Executive Assistant to the Chief Executive Officer and senior leadership team at Opto Investments in New York. Earlier in her career, Emily was an Executive Assistant to the President and Chief Executive Officer at CPP Investments in Toronto.Emily holds a Bachelor of Commerce from Royal Roads University.

George Hoyem is a distinguished venture capital executive and technology leader with over 25 years of experience spanning venture capital, entrepreneurship, and the national security intelligence sector. As Executive Vice President of Investments at In-Q-Tel (IQT)—the strategic venture capital arm of the CIA and U.S. Intelligence Community—George led a team that invested in more than 800 dual-use and defense-first startups. His focus areas included advanced analytics, AI, cloud, cybersecurity, and IT infrastructure, ensuring that critical emerging technologies reached national security agencies.

John is a seasoned AI and Data Science leader with experience as an Operator, Investor and Research Scientist.

Graham leads the productization of Intrepid's investment process, including the development of our internal AI platform.

Ttisa is an associate on the investment team in North America. Prior to Intrepid, Ttisa was an associate at CPP Investments, where she worked in its Leveraged Finance group, executing high-yield credit investments in the software space. Before joining the Leveraged Finance group full-time, Ttisa spent time as a rotational analyst at CPP, rotating across Growth Equity, Leveraged Finance, and Infrastructure.

Ophélie is an associate on the investment team in Europe. Prior to Intrepid, she worked at Morgan Stanley in London. She previously gained investing experience at World Fund, an early-stage venture fund in Munich, ENGIE’s corporate venture capital arm and a mid-cap private equity firm in Paris.

Jess is a senior associate on the investment team in Europe. Prior to Intrepid, Jess worked as an investor at ex/ante, investing across cybersecurity, AI, web3, and data infrastructure. She previously worked with CrossBoundary in Lebanon, Iraq, and Afghanistan as an investment advisor, where she worked on deals spanning tech, telco, and manufacturing. Jess also worked at Bain London, mostly within the PE due diligence ringfence, and with the UK Foreign Office, where she worked with the counter-ISIS taskforce in 2015.

Jess supports our sourcing and investing efforts in North America. Prior to Intrepid, Jess was a Senior Associate at General Atlantic in New York, where she executed growth and buyout investments and supported portfolio companies across the healthcare services industry, with a focus on value-based care, hospital partnership models, and behavioral health. Prior to GA, Jess was an Investment Banking Analyst at J.P. Morgan in New York, where she worked in the Healthcare group.

Grant helps lead our North America investing efforts and covers our investments in Beacon, CoLab, StackAdapt, and Blue J. Prior to Intrepid, Grant was an Associate at OMERS Growth Equity where he was part of the founding team and supported several direct investments in late-stage software and technology companies across Canada and the United States. He began his career as a Consultant at Monitor Deloitte where he advised clients on corporate strategy and operations with a focus on financial services.

Stephen helps lead our sourcing and investing efforts in the UK and Europe. Prior to Intrepid, Stephen was an investor with SoftBank Vision Fund and Atomico in London, where he worked with companies including Perk, Grab, Pipedrive, Bird (fka MessageBird), and Rovio.

Ajay Agrawal is the Geoffrey Taber Chair in Entrepreneurship and Innovation and Professor of Strategic Management at the University of Toronto’s Rotman School of Management.

My interest in technology began in the early 1980s when my brother and I received a TRS-80 for Christmas—an early and formative lesson in the power of automation to improve productivity. That instinct carried through to my years as an investment banker, where I built tools to automate routine workflows whenever I found time.

Mark trained in Physiological Sciences including specialization in neurosciences at Oxford, researched developmental biology, and studied Clinical Medicine at Cambridge before pursuing a career in finance. For more than two decades he worked at Goldman Sachs in Europe and Asia where he was a Partner and among other roles was Vice Chair and the Head of Investment Banking for Asia Pacific. He then joined CPPIB first as Head of International and then served as President and CEO for five years. Under his leadership, CPPIB grew its exposure to technology investing by launching a Venture and Growth Equity strategy, opening an office in San Francisco, and creating partnerships with leading venture firms and incubators, like the Creative Destruction Lab.

Jim Weiss advises Magnetic Ventures and is founder and chairman of Real Chemistry, which combines healthcare communications, data and technology. He began his corporate career at Genentech and has supported biopharma and digital health companies and research organizations.

Umut Eser is a Venture Partner at Magnetic Ventures, co-founder of Weave Bio and Head of Generative AI at Johnson & Johnson Innovative Medicines. He trained in applied physics at Stanford and computational biology at Harvard and previously held AI leadership roles at Quantum-Si, AI Therapeutics, Cellarity and Doctor Evidence.

Jillian Shaw is a Venture Partner at Magnetic Ventures, focused on AI-assisted drug discovery and precision genetic medicines. She is an Institute Scientist at the Broad Institute and co-leads its Ladders to Cures rare-disease accelerator. Her background includes synaptic physiology and neurodevelopmental disorders, with a PhD from USC and postdoctoral research at Stanford.

Christine Aylward founded Magnetic Ventures in 2018 and leads it as Managing Partner. She formerly served as a managing director at Foresite Capital and worked across healthcare innovation at Roche, Sanofi and Genomic Health. Her work spans technology, diagnostics and biotechnology investing. She is also a board member of Relation Therapeutics, confirmed by its current directory and financing announcement. She is also a director of Amydis, confirmed by both companies' current directories.

Serena Yang serves as Senior Analyst, Portfolio Operations at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Stephanie Yan serves as Senior Associate at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Liz Wuestling serves as Vice President, Business Analytics & Strategy at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Monet Uva serves as Office Operations Manager at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Tim Schmidt serves as Vice President, Fund Finance at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Katie Savage serves as Office Receptionist at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Elias Quijano serves as Principal at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Sarah Queen serves as Assistant Controller, Corporate Finance at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Hyewon Park serves as Assistant Controller, Funds at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Wes Long serves as Senior Analyst at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Andrew Lee serves as Managing Director at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Ivan Learmont serves as Vice President, Information Technology & Facilities at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Maggie Kehoe serves as Senior Executive Assistant at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Anjali Jagannath serves as Vice President, Finance at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Ben Hartheimer serves as Senior Associate, Portfolio Operations at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Catherine Gamble serves as Manager, Corporate Finance at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Nick Futrell serves as Senior Associate at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Alexis Fleming serves as Manager, Portfolio Operations & Administration at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Daniella Doolen serves as Executive Assistant at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Ashley Cowher serves as Senior Executive Assistant at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Madison Bedwell serves as Executive Assistant at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Lydia Allison serves as Executive Assistant at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Pat Smerkers serves as Chief Financial Officer, Partner at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Andrea Jackson serves as Partner at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Sharon Kedar serves as Co-Founder, Partner at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Michael P. Rubin serves as Founder & CEO at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Entrepreneur in medical device distribution and pharmaceutical development in Taiwan and China, including Progressive Group and Sino Pharma.

Medical technology executive with previous leadership roles at CardioNet, Viasys Healthcare and Respironics.

Medical technology licensing and robotics entrepreneur with experience at Non-Invasive Technology and U.S. Robots.

Biomedical engineering scientist at Drexel University specialising in signals, systems and biomedical signal processing.

Electrical engineer experienced in medical device development, manufacturing and communications equipment, formerly at Valley Forge Scientific.

International sales and distribution executive with previous experience at Kodak Graphic Arts.

Medical technology commercial leader with previous sales leadership roles at Z-Medica and Olympus America.

Physicist and medical device executive with electro-optics, ophthalmic imaging and medical laser commercialisation experience.

Venture capital professional identified by BioAdvance as a partner at First Round Capital.

Physician and biotechnology executive, chairman and chief executive of Cabaletta Bio and adjunct professor at the Wharton School, as identified in BioAdvance’s board directory.

Former managing director of alternative investments at the Pennsylvania State Employees’ Retirement System.

Deputy secretary for technology and entrepreneurship at Pennsylvania’s Department of Community and Economic Development, as identified in BioAdvance’s board directory.

President emeritus and Linwood F. Tice Professor emeritus at the University of the Sciences.